Analysts Set Expectations for OKUR FY2025 Earnings

OnKure Therapeutics (NASDAQ:OKUR) – Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for OnKure Therapeutics in a report released on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($5.14) per share for the year. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share.

OnKure Therapeutics (NASDAQ:OKUR) last announced its earnings results on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51).

A number of other research firms have also issued reports on OKUR. Leerink Partners started coverage on shares of OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 target price on the stock. Oppenheimer reduced their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $34.33.

OnKure Therapeutics Trading Down 0.2 %

NASDAQ OKUR opened at $4.61 on Thursday. The stock has a market capitalization of $15.41 million, a price-to-earnings ratio of -0.38 and a beta of 0.28. The company has a 50 day simple moving average of $5.73. OnKure Therapeutics has a one year low of $4.45 and a one year high of $20.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC acquired a new stake in shares of OnKure Therapeutics in the 4th quarter valued at $12,381,000. Geode Capital Management LLC purchased a new position in OnKure Therapeutics in the fourth quarter valued at $659,000. Boothbay Fund Management LLC acquired a new stake in OnKure Therapeutics in the fourth quarter valued at $671,000. Samsara BioCapital LLC purchased a new stake in OnKure Therapeutics during the 4th quarter worth about $7,088,000. Finally, XTX Topco Ltd purchased a new stake in OnKure Therapeutics during the 4th quarter worth about $160,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.